Business Wire

Cloudreach and AWS Sign Strategic Collaboration Agreement to Accelerate Global Cloud Adoption

11.8.2021 12:00:00 EEST | Business Wire | Press release

Share

Cloudreach, a leading independent cloud services provider, and Amazon Web Services (AWS), today unveiled a new Strategic Collaboration Agreement. The wide-ranging agreement will mean an acceleration of the companies’ joint go-to-market proposition, along with investments in Cloudreach software innovation, geographical expansion and the launch of a Talent Academy.

This agreement builds on the well-established 12-year relationship between Cloudreach and AWS. Cloudreach will expand within North America and Europe including into new territories Canada, Poland, Spain and the Nordics. In addition, Cloudreach will make significant investments in software, further developing its SMART Migration™ and SMART Modernization™ services. These services are designed to accelerate enterprise cloud adoption through intelligent automation and will help more customers to realize the benefits of AWS services with far greater efficiency.

Cloudreach CEO, Brooks Borcherding, said: “After 12 years of collaboration with AWS, we’re excited to be entering this new phase of growth. Together, we’re focused on delivering the promise of the cloud through new software-driven capabilities coupled with industry-best practices and expertise. For our customers this will mean adopting AWS cloud more efficiently and with greater confidence, achieving a faster time to value.”

Launch of Cloudreach Talent Academy

A key initiative within the agreement is the launch of a Talent Academy. The Academy is designed to train hundreds of diverse and promising candidates to become the next generation of cloud professionals. For entry into the program, Cloudreach will look for candidates with a passion for building their career in cloud, even if they do not have a technical background, and fast-track their technical development.

The program will bring more talent into the AWS community, offering candidates a path to acquire and upskill their AWS capabilities. The Talent Academy is unique in its emphasis on recruiting from a diverse pool of candidates who traditionally have not selected technical career paths. Cloudreach expects hundreds of candidates to become AWS-certified and get the hands-on experience to become cloud consultants, engineers, architects, and developers.

“Cloudreach is committed to addressing underrepresentation and the lack of diversity within the technology workforce and cloud industry. This purpose-driven investment is one of the most exciting aspects of this collaboration with AWS. We’re dedicated to be helping future professionals develop their careers where they will solve complex business challenges for our joint customers,” added Borcherding.

Doug Yeum, Head of Worldwide Channels and Alliances at AWS, said: “We are delighted to build upon the 12-year relationship with AWS Premier Partner, Cloudreach. This collaboration means AWS can bring the highest level of cloud native expertise to an even wider audience with Cloudreach, significantly accelerating the pace of global cloud adoption. We are also particularly appreciative of Cloudreach’s focus on expanding the diverse talent pool of AWS-skilled professionals, which aligns with our leadership principles as a company.”

This engagement will provide AWS and Cloudreach customers with compelling new SMART Migration™ and SMART Modernization™ service offerings to dramatically accelerate cloud adoption and reduce time-to-value by 40%. These new offerings leverage both Cloudamize, a leading planning, assessment, and migration automation software, and Sunstone, a cloud modernization machine learning engine to make continuous modernization recommendations for legacy and cloud deployed services.

Marie Measures, Chief Technology Officer at Sanne Group, the alternative asset fund administrator, said: “The possibilities are endless when you engage with an AWS Partner that’s flexible, easy to work with, and shares your organization’s values. We want to move quickly along our cloud journey and, thanks to Cloudreach and AWS, we have a well-structured transformational roadmap.”

For more details about the collaboration between AWS and Cloudreach, please visit: www.cloudreach.com/en/partners/aws-premier-consulting-partner/

– ENDS –

About Cloudreach

Cloudreach is the world’s leading independent cloud services company. Our mission is to deliver the promise of cloud and drive extraordinary value for our customers. Cloudreach helps enterprises win competitive advantage through successful cloud transformation. With more than 10 years of cloud native experience, we’ve built an unmatched depth and breadth of expertise in cloud technologies and their application to business. For more information about our work, visit www.cloudreach.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press Contact
Rahim Hakimi
Email: rahim.hakimi@cloudreach.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye